Overview
PYPD market data
Price History
PYPD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.44 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.06 – $5.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $71.6 · P/B 6.29.
Company News
PolyPid shares are trading higher after the company announced that the FDA accepted its New Drug Application and granted it a Priority Review for D-PLEX100Benzinga · Jul 29, 2026, 12:50 PM
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28Benzinga · Jul 29, 2026, 12:34 PM
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price TargetBenzinga · Jul 21, 2026, 3:58 PM
PolyPid shares are trading lower. The company announced it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100.Benzinga · Jul 21, 2026, 2:30 PM
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront PaymentBenzinga · Jul 21, 2026, 11:32 AM
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site InfectionsBenzinga · Jun 1, 2026, 12:40 PM
PolyPid Q1 2026 Earnings Call: Complete TranscriptBenzinga · May 13, 2026, 1:24 PM
PolyPid Q1 EPS $(0.35) Beats $(0.43) EstimateBenzinga · May 13, 2026, 11:31 AM
Earnings Scheduled For May 13, 2026Benzinga · May 13, 2026, 11:11 AM